Ligand Pharmaceuticals Announces Second Quarter Results
Ligand to Report Second Quarter Results on August 8th
Ligand Partner GlaxoSmithKline Receives Positive Data from Promacta(R) PIII ENABLE1 Study in Hepatitis C-Related Thrombocytopenia
Ligand to Advance Clinical Development of Captisol-enabled(R), Propylene Glycol-Free Melphalan for Multiple Myeloma
Reminder: Ligand to Webcast Analyst and Investor Day on June 23 in New York City
Ligand Enters into Captisol(R) Commercial Supply Agreement with Merck
Ligand Presents Phase IIa Data on Captisol(R)-Enabled, Propylene Glycol-Free Melphalan at ASCO 2011
Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting
Ligand to Webcast Analyst and Investor Day on June 23 in New York City
Ligand Pharmaceuticals Reports First Quarter Results
Ligand to Report First Quarter Results on May 10th
Ligand Partner Prism Pharmaceuticals to be Acquired by Baxter
Ligand Names Matthew W. Foehr Chief Operating Officer
Ligand to Present at the Citi 2011 Global Healthcare Conference on March 2
